Open AccessCombination therapy with dendritic cell-based vaccine and anti-CD69 antibody enhances antitumor efficacy in renal cell carcinoma-bearing mice
Author(s) -
Si-Ming Wei,
Hang-Li Pan,
Li Wang,
Guo-Li Yin,
Kai Zhong,
Ya Zhou,
Shu-Jiao Yang,
Zhao-Liang Xin
Publication year - 2017
Publication title -
turkish journal of medical sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.277
H-Index - 27
eISSN - 1303-6165
pISSN - 1300-0144
DOI - 10.3906/sag-1601-198
Subject(s) - medicine , dendritic cell , antibody , immunotherapy , cancer research , renal cell carcinoma , immunology , t cell , cell , immune system , pathology , biology , genetics
Dendritic cell-based vaccine therapy for renal cell carcinoma is effective but requires improvement. Here we explored whether combination therapy with dendritic cell-based vaccine and anti-CD69 antibody can enhance antitumor efficacy in renal cell carcinoma-bearing mice.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom